Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
MIGRANAL is a nasal spray formulation of dihydroergotamine mesylate, an ergot alkaloid used for acute migraine treatment. It works as a vasoconstrictor and acts on serotonin receptors to relieve migraine symptoms. The metered-dose nasal spray provides rapid systemic delivery for patients seeking non-oral migraine relief.
Minimal commercial activity with low spending and claim volume signals a small, mature product likely consolidating resources or in transition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Working on MIGRANAL offers limited growth opportunity given its LOE-approaching lifecycle and minimal job pipeline (0 linked positions). Career professionals should expect focus on operational efficiency, managed decline, and transition planning rather than market expansion or innovation.
Worked on MIGRANAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo